Title Neoadjuvant chemotherapy followed by gastrectomy for cytology-positive gastric cancer without any other non-curative factors in a western setting: an International Eastern European cohort study
Authors Baušys, Augustinas ; Ümarik, Toomas ; Dobrzhanskyi, Oleksii ; Lukšta, Martynas ; Kondratskyi, Yourii ; Reinsoo, Arvo ; Vassiljev, Mihhail ; Baušys, Bernardas ; Bičkaitė, Klaudija ; Rauduvytė, Kornelija ; Lukšaitė-Lukštė, Raminta ; Baušys, Rimantas ; Strupas, Kęstutis
DOI 10.3390/cancers15245794
Full Text Download
Is Part of Cancers.. Basel : MDPI AG. 2023, vol. 15, iss. 24, art. no. 5794, p. [1-13].. eISSN 2072-6694
Keywords [eng] gastric cancer ; positive cytology ; neoadjuvant chemotherapy ; pathological response
Abstract [eng] The optimal approach for treating cytology-positive (Cy1) gastric cancer (GC) patients without additional non-curative factors remains uncertain. While neoadjuvant chemotherapy followed by gastrectomy shows promise, its suitability for Western patients is not well supported by existing data. To address this knowledge gap, a cohort study was conducted across four major GC treatment centers in Lithuania, Estonia, and Ukraine. Forty-three consecutive Cy1 GC patients who underwent neoadjuvant chemotherapy between 2016 and 2020 were enrolled. The study evaluated overall survival (OS), progression-free survival (PFS), cytology status conversion, and major pathological response rates, along with the factors influencing these outcomes. All patients underwent surgery post-neoadjuvant chemotherapy, with 53.5% experiencing cytological status conversion and 23.3% achieving a major pathological response. The median OS and PFS were 20 (95% CI: 16–25) and 19 (95% CI: 11–20) months, respectively. Conversion to negative cytology significantly reduced the relative risk of peritoneal progression (RR: 0.11; 95% CI: 0.03–0.47, p = 0.002). The study suggests that neoadjuvant chemotherapy followed by gastrectomy holds promise as a treatment option for Cy1 GC without additional non-curative factors, associating cytology status conversion with improved long-term outcomes and reduced peritoneal relapse risk.
Published Basel : MDPI AG
Type Journal article
Language English
Publication date 2023
CC license CC license description